| ID_events | cancer | TypeID | ImmuneCell | P | R | CorrelationPlot |
| ENSG00000178381.10,ZFAND2A | BLCA | EAG | Macrophages_M2 | 4.2179e-02 | -0.3270 |  |
| ENSG00000178381.10,ZFAND2A | BRCA | EAG | Dendritic_cells_activated | 3.2250e-02 | -0.3793 |  |
| ENSG00000178381.10,ZFAND2A | CESC | EAG | T_cells_regulatory_(Tregs) | 3.1888e-02 | 0.3743 | .ENSG00000178381.10,ZFAND2A.png) |
| ENSG00000178381.10,ZFAND2A | COAD | EAG | T_cells_regulatory_(Tregs) | 2.7068e-02 | -0.4034 | .ENSG00000178381.10,ZFAND2A.png) |
| ENSG00000178381.10,ZFAND2A | GBM | EAG | T_cells_gamma_delta | 8.1502e-05 | 0.5759 |  |
| ENSG00000178381.10,ZFAND2A | HNSC | EAG | Dendritic_cells_activated | 2.9357e-02 | -0.4196 |  |
| ENSG00000178381.10,ZFAND2A | LAML | EAG | Dendritic_cells_resting | 1.6256e-02 | 0.4424 |  |
| ENSG00000178381.10,ZFAND2A | LGG | EAG | Dendritic_cells_resting | 1.3958e-02 | -0.4370 |  |
| chr7:1153296-1155058:- | LIHC | EER | Mast_cells_activated | 1.1770e-02 | 0.4045 |  |
| ENSG00000178381.10,ZFAND2A | LIHC | EAG | Mast_cells_activated | 1.1887e-02 | 0.4040 |  |
| chr7:1153296-1155058:- | LUAD | EER | Macrophages_M2 | 3.4003e-02 | 0.3004 |  |
| ENSG00000178381.10,ZFAND2A | LUAD | EAG | Macrophages_M2 | 3.3997e-02 | 0.3005 |  |
| ENSG00000178381.10,ZFAND2A | LUSC | EAG | T_cells_follicular_helper | 4.1389e-02 | -0.2925 |  |
| ENSG00000178381.10,ZFAND2A | PAAD | EAG | Macrophages_M0 | 8.0101e-03 | -0.4908 |  |
| ENSG00000178381.10,ZFAND2A | PRAD | EAG | Macrophages_M1 | 1.9072e-02 | -0.4326 |  |
| chr7:1153296-1155058:- | STAD | EER | T_cells_CD8 | 1.9172e-02 | 0.3405 |  |
| ENSG00000178381.10,ZFAND2A | STAD | EAG | T_cells_CD8 | 8.4796e-03 | 0.3684 |  |
| ENSG00000178381.10,ZFAND2A | TGCT | EAG | B_cells_naive | 4.4357e-02 | 0.4054 |  |
| ID_events | cancer | HallmarkType | Type | P | R | CorrelationPlot |
| ENSG00000178381.10,ZFAND2A | BLCA | GSVA_HALLMARK_DNA_REPAIR | EAG | 6.2232e-03 | 0.4305 |  |
| ENSG00000178381.10,ZFAND2A | CESC | GSVA_HALLMARK_SPERMATOGENESIS | EAG | 2.0958e-02 | -0.4004 |  |
| ENSG00000178381.10,ZFAND2A | COAD | GSVA_HALLMARK_SPERMATOGENESIS | EAG | 4.1501e-02 | 0.3744 |  |
| ENSG00000178381.10,ZFAND2A | ESCA | GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB | EAG | 6.0745e-03 | -0.3475 |  |
| chr7:1153296-1155058:- | ESCA | GSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKB | EER | 2.1640e-03 | -0.3916 |  |
| ENSG00000178381.10,ZFAND2A | GBM | GSVA_HALLMARK_FATTY_ACID_METABOLISM | EAG | 7.9939e-03 | 0.4086 |  |
| ENSG00000178381.10,ZFAND2A | HNSC | GSVA_HALLMARK_BILE_ACID_METABOLISM | EAG | 8.6628e-03 | 0.4950 |  |
| ENSG00000178381.10,ZFAND2A | KIRC | GSVA_HALLMARK_GLYCOLYSIS | EAG | 4.6609e-02 | -0.4285 |  |
| ENSG00000178381.10,ZFAND2A | LIHC | GSVA_HALLMARK_XENOBIOTIC_METABOLISM | EAG | 4.4628e-02 | 0.3277 |  |
| chr7:1153296-1155058:- | LIHC | GSVA_HALLMARK_XENOBIOTIC_METABOLISM | EER | 4.4298e-02 | 0.3281 |  |
| ENSG00000178381.10,ZFAND2A | LUAD | GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE | EAG | 1.4518e-03 | -0.4384 |  |
| chr7:1153296-1155058:- | LUAD | GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE | EER | 1.4624e-03 | -0.4381 |  |
| ENSG00000178381.10,ZFAND2A | LUSC | GSVA_HALLMARK_TGF_BETA_SIGNALING | EAG | 2.4072e-03 | 0.4238 |  |
| chr7:1153296-1155058:- | OV | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EER | 8.4026e-03 | 0.5592 |  |
| ENSG00000178381.10,ZFAND2A | OV | GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION | EAG | 3.0156e-03 | 0.5904 |  |
| ENSG00000178381.10,ZFAND2A | PAAD | GSVA_HALLMARK_MITOTIC_SPINDLE | EAG | 2.9671e-03 | -0.5408 |  |
| ID_events | cancer | Drug | Type | P | R | CorrelationPlot |
| ENSG00000178381.10,ZFAND2A | BLCA | BI.2536 | EAG | 8.8800e-04 | -0.5109 |  |
| ENSG00000178381.10,ZFAND2A | CESC | LFM.A13 | EAG | 2.5510e-02 | -0.3884 |  |
| ENSG00000178381.10,ZFAND2A | COAD | Doxorubicin | EAG | 8.4867e-03 | 0.4718 |  |
| ENSG00000178381.10,ZFAND2A | ESCA | Midostaurin | EAG | 6.7061e-03 | -0.3436 |  |
| chr7:1153296-1155058:- | ESCA | Midostaurin | EER | 6.2528e-03 | -0.3520 |  |
| ENSG00000178381.10,ZFAND2A | GBM | AICAR | EAG | 1.7917e-03 | 0.4730 |  |
| ENSG00000178381.10,ZFAND2A | HNSC | CGP.60474 | EAG | 6.0868e-03 | -0.5141 |  |
| ENSG00000178381.10,ZFAND2A | KIRC | GDC0941 | EAG | 3.4841e-03 | -0.5951 |  |
| ENSG00000178381.10,ZFAND2A | LAML | KU.55933 | EAG | 2.7876e-03 | -0.5350 |  |
| ENSG00000178381.10,ZFAND2A | LIHC | CGP.60474 | EAG | 6.1599e-03 | -0.4364 |  |
| chr7:1153296-1155058:- | LIHC | CGP.60474 | EER | 6.3105e-03 | -0.4353 |  |
| ENSG00000178381.10,ZFAND2A | LUAD | Docetaxel | EAG | 5.9503e-03 | 0.3837 |  |
| chr7:1153296-1155058:- | LUAD | Docetaxel | EER | 5.9557e-03 | 0.3836 |  |
| ENSG00000178381.10,ZFAND2A | LUSC | CCT007093 | EAG | 2.4763e-04 | -0.5008 |  |
| chr7:1153296-1155058:- | OV | Imatinib | EER | 2.5006e-03 | 0.6240 |  |
| ENSG00000178381.10,ZFAND2A | OV | Imatinib | EAG | 7.8503e-04 | 0.6501 |  |
| ENSG00000178381.10,ZFAND2A | PAAD | FTI.277 | EAG | 1.1720e-03 | 0.5815 |  |
| ENSG00000178381.10,ZFAND2A | PRAD | GW843682X | EAG | 5.5157e-03 | -0.5021 |  |
| chr7:1153296-1155058:- | SKCM | AZD.2281 | EER | 8.0369e-03 | 0.5384 |  |
| ENSG00000178381.10,ZFAND2A | SKCM | AZD.2281 | EAG | 8.0589e-03 | 0.5383 |  |
| chr7:1153296-1155058:- | STAD | Cyclopamine | EER | 5.0674e-03 | -0.4022 |  |
| ENSG00000178381.10,ZFAND2A | STAD | Cyclopamine | EAG | 7.9098e-03 | -0.3714 |  |